Navigation Links
M2S, Inc. Acquires DXA Resource Group; Expands Core Capabilities in Clinical Trial Image Management
Date:1/6/2009

M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials, announced today that the company has acquired DXA Resource Group (DRG) of Westborough, Mass.

(PRWEB) January 6, 2009 -- M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials, announced today that the company has acquired DXA Resource Group (DRG) of Westborough, Mass.

Founded in 2002, DRG recognized the need for cost-effective and responsive DXA (Dual- Emission X-Ray Absorptiometry) clinical quality assurance, project management and data management services to support drug development. DXA, a low-dose (1/10th of traditional x-ray) imaging modality that measures bone mineral density and body mass composition, is increasingly utilized in clinical trials to assess the safety and effectiveness of drugs under development for indications such as osteoporosis, HIV, obesity, growth hormone deficiency, endometriosis, fibroids and Gaucher's disease.

"DRG has integrated quality service with imaging data technology, which exactly fits into the M2S mission and clinical trials image management service offering. The addition of DRG allows M2S to further expand our capabilities and therapeutic expertise, and meet the growing demand for image management services worldwide," M2S CEO Wes Chapman said.

"Adding M2S high-speed image collection and trial management technologies to DRG's proprietary quality system and data management, enables us to greatly increase our presence in the drug development market," said Reta Rupic
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

5

GOOD

Page: 1 2

Related medicine news :

1. The Ensign Group Acquires Texas Skilled Nursing Facility
2. The Ensign Group Acquires California Skilled Nursing Facility
3. IPC The Hospitalist Company Acquires Two Florida Practices
4. ProAssurance Acquires Mid-Continent General Agency to Expand Ancillary Healthcare Insurance Business
5. Bi-Coastal Pharmaceutical Corp. Acquires U.S. Marketing Rights to Aquoral(TM) Artificial Saliva Product
6. Unilens Vision Acquires Aero Contact Lens, Inc.
7. AdCare Health Systems, Inc. Acquires Remaining Ownership in Van Wert Assisted Living Property
8. The Ensign Group, Inc. Acquires Utah Skilled Nursing Facility
9. Fujifilm Acquires Information Systems Vendor Empiric
10. AETEA Acquires ecipient Technologies
11. Capital BlueCross Acquires Dominion Dental
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
M2S, Inc. Acquires DXA Resource Group; Expands Core Capabilities in Clinical Trial Image Management 
M2S, Inc. Acquires DXA Resource Group; Expands Core Capabilities in Clinical Trial Image Management
(Date:7/3/2009)... ReverseAges.com launches new content to ...enal fatigue, and how to best deal with these heal...A (PRWEB) July 3, 2009 -- ReverseAges.com has rece...xplain the dangers of common health issues such as...d by a variety of factors, and the new content on ...
(Date:7/3/2009)... Upstate HomeCare, a home medical service...ication, respiratory and DME services, is expandin.... One specializes in home infusion therapy and one...e HomeCare. , Clinton, NY...me medical services provider specializing in infus...
(Date:7/2/2009)...rge State Leaders to Support Principles to Govern ... July 2 Nearly nine out... companies have too much influence over how doctor...%) voters support the concept of a "Health Insurer...uiding principles for health insurance companies w...
(Date:7/2/2009)...y 2 Pro-life forces won...me Court ruled to uphold a state law regulating th...lines in administering RU-486 (also known as the "...women using the drug. , , The ruling came in ...ned Parenthood to a 2004 law requiring that those ...
Breaking Medicine News(10 mins):Health News:Upstate HomeCare Expands, Adds Pharmacies 2Health News:Upstate HomeCare Expands, Adds Pharmacies 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 2Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 4Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 5Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 6Health News:Ohio Supreme Court Strikes a Blow to Planned Parenthood in Upholding Regulation of 'Abortion Pill' 2
...ood letting in patients with peripheral artery dis...age//. This finding was published in the February ...on. Iron deposit in the body is considered a risk...ence reducing iron from the body may have a positi...
...ation (FDA) has come out with a warning to consume...have administered doses of the vaccine Rota Teq, t...eption. The vaccine is given to infants between 2...n optional vaccine to prevent infection by rotavir...
... was diagnosed with lung cancer has won $ 1 millio...e// is currently suffering from an inoperable lung...maximum eighteen months of life. At this juncture,...y that is accompanying this lottery win is that he...
...ersity in Chicago claim that men who have undergon...of dementia. This study was published in Cognitive...ducted on 106 men. Out of this, 25 developed a dem... (PPA) who had also undergone vasectomy. According...
Other Medicine News:
(Date:6/30/2009)...TERDAM, The Netherlands, June 30 ,...cision-Making Process With,Respect to Infertility...lysis presented today at this year,s,European Soc...congress showed,that, within the parameters of th...on (IVF) treatment MENOPUR (highly-purified human ...
(Date:6/29/2009)...arma Targets for Novel Biotherapeutics Based On Na...O, June 29 Pangu BioPharma, a subs...d the filing of its third patent application on pr...A synthetases. Although tRNA synthetases are univ...s machinery found in all organisms, human syntheta...
(Date:6/28/2009)...PPENHAM, England and TOKYO, June 29 /PRNewswire/ -...oth Companies , Sosei Group Corporation ("S... plc ("Vectura"; LSE: VEC) announce the commenceme...h NVA237, a once-daily, long-acting muscarinic,an...uctive pulmonary disease,(COPD). NVA237 is a dry ...
(Date:6/26/2009)...nation of Inherited and New Genetic Mutations Acti...wire-USNewswire/ -- More pieces in the complex aut...study from a research team including geneticists f...University of Pennsylvania School of Medicine and...entified 27 different genetic regions where rare c...
Breaking Medicine Technology:New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 2New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 3New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 4Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4More Gene Mutations Linked to Autism Risk 2More Gene Mutations Linked to Autism Risk 3More Gene Mutations Linked to Autism Risk 4CryoLifes Earnings Per Share Increased 180 Percent to 240 14 in Second Quarter of 2008 from 240 05 in Second Quarter of 2007 6853 1CryoLifes Earnings Per Share Increased 180 Percent to 240 14 in Second Quarter of 2008 from 240 05 in Second Quarter of 2007 6853 2CryoLifes Earnings Per Share Increased 180 Percent to 240 14 in Second Quarter of 2008 from 240 05 in Second Quarter of 2007 6853 3CryoLifes Earnings Per Share Increased 180 Percent to 240 14 in Second Quarter of 2008 from 240 05 in Second Quarter of 2007 6853 4CryoLifes Earnings Per Share Increased 180 Percent to 240 14 in Second Quarter of 2008 from 240 05 in Second Quarter of 2007 6853 5CryoLifes Earnings Per Share Increased 180 Percent to 240 14 in Second Quarter of 2008 from 240 05 in Second Quarter of 2007 6853 6CryoLifes Earnings Per Share Increased 180 Percent to 240 14 in Second Quarter of 2008 from 240 05 in Second Quarter of 2007 6853 7CryoLifes Earnings Per Share Increased 180 Percent to 240 14 in Second Quarter of 2008 from 240 05 in Second Quarter of 2007 6853 8CryoLifes Earnings Per Share Increased 180 Percent to 240 14 in Second Quarter of 2008 from 240 05 in Second Quarter of 2007 6853 9CryoLifes Earnings Per Share Increased 180 Percent to 240 14 in Second Quarter of 2008 from 240 05 in Second Quarter of 2007 6853 10CryoLifes Earnings Per Share Increased 180 Percent to 240 14 in Second Quarter of 2008 from 240 05 in Second Quarter of 2007 6853 11Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 1Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 2Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 3Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 4Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 5Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 6Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 7Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 8Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 9Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 10Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 11Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 12Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 13Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 14Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 15Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 16Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 17Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 18Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 19Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 20Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 21Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 22Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 23Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 24Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 25Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 26Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 27Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 28Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 29Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 30Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 31Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 32Shire Delivers Strong Quarter 3A Driven by 24243m of New Product Sales 28+164 25 YOY Growth 29 Revenue Guidance Upgrade 6850 33Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials 2759 1Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials 2759 2Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of 24 10 on Revenues of 2427 6 Million 24724 1Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of 24 10 on Revenues of 2427 6 Million 24724 2Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of 24 10 on Revenues of 2427 6 Million 24724 3Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of 24 10 on Revenues of 2427 6 Million 24724 4Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of 24 10 on Revenues of 2427 6 Million 24724 5
...Digestive Disease Week -, CAMBRIDGE, Mass., May 21...e presentation of data from a Phase 2 study in whi...roved bowel function,in patients with constipation...ese data also showed linaclotide was well tolerate...ide is a first-in-class,compound currently being d...
...--May 21, 2007 - Antigenics Inc.,(NASDAQ: AGEN) to...pany,s Phase 3 investigational therapeutic cancer ...results, which reflect an,additional 17 months, da... of patients (n = 362) at intermediate risk for di...lly significant,improvement in recurrence-free sur...
Other Medicine Technology:Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 2Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 3Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 4Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 2Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 3Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 4Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 5Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 6
Derived from an extensive study into increasing the range of motion in hip replacement, the cemented SHP acetabular cup is a unique design and is manufactured from ArCom polyethylene.
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects.
Duraloc 400 series cup.
The Trident PSL Acetabular Shells are designed to maximize fixation in the peripheral lunate region of the acetabulum.
Medicine Products: